European Patent Office issues notice of intent to grant patent for Nuvo Research's PENNSAID 2%

Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain today announced that the European Patent Office has issued a notice of Intention to Grant a European Patent that provides protection for the Company's PENNSAID^® 2% product. Upon grant by the European Patent Office, the patent can be officially validated in over 37 European countries.

PENNSAID 2% is protected by issued patents in the United States expiring April 21, 2028 and in New Zealand, South Africa and the Russian Federation with an expiration date of October 17, 2027. Patent applications covering PENNSAID 2% are currently pending in Australia, Brazil, Canada, China, Hong Kong, India, Israel, Japan and Mexico and have an anticipated expiry date of October 17, 2027.

The Company is currently in discussions with potential marketing partners interested in licensing PENNSAID and/or PENNSAID 2% for Europe, Russia, China, the Middle East, Asia and Australia.

"We are very pleased with the progress we are making to secure worldwide patent protection for our next generation topical NSAID, PENNSAID 2%," said Tina Loucaides , Nuvo's Vice-President and General Counsel.  "This expanding patent portfolio supports our efforts to secure international licensing partners for PENNSAID 2% and additional sources of revenue for Nuvo."